It is also worth pointing out that upon DR-CHOP treatment, TP53mut DLBCL obtained 3-year PFS and 3-year OS with 72.1% and 79.1%, respectively, similar to TP53wt DLBCL that received R-CHOP.7 Collectively, our findings highlighted a TP53/SUV39H1/H3K9me3 regulatory circuitry and assigned ERVs as promising therapeutic targets in cancer treatment. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.